These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35795235)

  • 1. Depressive Symptoms Have Distinct Relationships With Neuroimaging Biomarkers Across the Alzheimer's Clinical Continuum.
    Moulinet I; Touron E; Mézenge F; Dautricourt S; De La Sayette V; Vivien D; Marchant NL; Poisnel G; Chételat G
    Front Aging Neurosci; 2022; 14():899158. PubMed ID: 35795235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective cognitive decline: opposite links to neurodegeneration across the Alzheimer's continuum.
    Kuhn E; Perrotin A; Tomadesso C; André C; Sherif S; Bejanin A; Touron E; Landeau B; Mezenge F; Vivien D; De La Sayette V; Chételat G;
    Brain Commun; 2021; 3(3):fcab199. PubMed ID: 34704027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.
    Kuhn E; Moulinet I; Perrotin A; La Joie R; Landeau B; Tomadesso C; Bejanin A; Sherif S; De La Sayette V; Desgranges B; Vivien D; Poisnel G; Chételat G
    Alzheimers Res Ther; 2019 Jul; 11(1):61. PubMed ID: 31286994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition.
    Dicks E; Vermunt L; van der Flier WM; Barkhof F; Scheltens P; Tijms BM;
    Brain Commun; 2020; 2(2):fcaa177. PubMed ID: 33376987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirically defining the preclinical stages of the Alzheimer's continuum in the Alzheimer's Disease Neuroimaging Initiative.
    Kiselica AM;
    Psychogeriatrics; 2021 Jul; 21(4):491-502. PubMed ID: 33890392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition.
    Vemuri P; Weigand SD; Przybelski SA; Knopman DS; Smith GE; Trojanowski JQ; Shaw LM; Decarli CS; Carmichael O; Bernstein MA; Aisen PS; Weiner M; Petersen RC; Jack CR;
    Brain; 2011 May; 134(Pt 5):1479-92. PubMed ID: 21478184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Cognitive Profiles by Anxiety and Depressive Symptoms in American Older Adults With Subjective Cognitive Decline.
    Ahn S; Mathiason MA; Yu F
    J Nurs Scholarsh; 2021 Nov; 53(6):698-708. PubMed ID: 34342395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-specificities in anxiety and depressive symptoms across the lifespan and their links with multimodal neuroimaging.
    Moulinet I; Landeau B; Touron E; De La Sayette V; Desgranges B; Vivien D; Marchant N; Poisnel G; Chételat G
    J Affect Disord; 2022 Jan; 296():593-602. PubMed ID: 34637806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
    Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
    J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
    [No Abstract]   [Full Text] [Related]  

  • 12. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activities of Daily Living and Depressive Symptoms in Patients with Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Stogmann E; Moser D; Klug S; Gleiss A; Auff E; Dal-Bianco P; Pusswald G; Lehrner J
    J Alzheimers Dis; 2016; 49(4):1043-50. PubMed ID: 26577522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers.
    Salvadó G; Shekari M; Falcon C; Operto G; Milà-Alomà M; Sánchez-Benavides G; Cacciaglia R; Arenaza-Urquijo E; Niñerola-Baizán A; Perissinotti A; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Molinuevo JL; Zetterberg H; Blennow K; Suárez-Calvet M; Gispert JD;
    Brain Commun; 2022; 4(3):fcac134. PubMed ID: 35702732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
    Nakamura A; Cuesta P; Fernández A; Arahata Y; Iwata K; Kuratsubo I; Bundo M; Hattori H; Sakurai T; Fukuda K; Washimi Y; Endo H; Takeda A; Diers K; Bajo R; Maestú F; Ito K; Kato T
    Brain; 2018 May; 141(5):1470-1485. PubMed ID: 29522156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Yew B; Nation DA;
    Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.
    Racine AM; Koscik RL; Berman SE; Nicholas CR; Clark LR; Okonkwo OC; Rowley HA; Asthana S; Bendlin BB; Blennow K; Zetterberg H; Gleason CE; Carlsson CM; Johnson SC
    Brain; 2016 Aug; 139(Pt 8):2261-74. PubMed ID: 27324877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.
    Pietrzak RH; Lim YY; Neumeister A; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Restrepo C; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P;
    JAMA Psychiatry; 2015 Mar; 72(3):284-91. PubMed ID: 25629787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.